Ambrisentan as film coated immediate-release tablets was provided by Myogen, Inc.

Test Commercial Formulations

They were manufactured by

- ambrisentan mg tablets for oral administration debossed on one side and on the other side, Lot No. R0135002 (Lot No. L0101702, expiration date December 2006), manufactured by drug substance Batch 3109.F.04.4 having a of

- Square, pale-pink ambrisentan 5 mg tablets for oral administration debossed on one side and “5” on the other side, Lot No. R0136002 (Lot No. L0101701, expiration date December 2006), manufactured by drug substance Batch 3109.F.04.4 having a of

- Oval, dark-pink ambrisentan 10mg tablets for oral administration debossed on one side and “10” on the other side, Lot No. R0137002 (Lot No. L0101699, expiration date December 2006), manufactured by drug substance Batch 3109.F.04.4 having a of

- Oval, dark-pink ambrisentan 10 mg tablets for oral administration debossed on one side and “10” on the other side, Lot No. R0137001 (Lot No. L0101704, expiration date December 2006), manufactured by drug substance Batch 3109.F.04.2 having a of

Reference Clinical Formulations

They were manufactured by

- pink, ambrisentan tablets for oral administration, Lot No. 171022292, expiration date January 2007, Lot No. 280200A0, expiration date January 2007), manufactured by drug substance Batch L0003139 (Lot No. L0001849) having a of

- pink, ambrisentan 5 mg tablets for oral administration Lot No. 171022330, expiration date January 2007, Lot No. 280200A0, expiration date January 2007), manufactured by drug substance Batch L0003139 (Lot No. L0001851) having a of

- pink, ambrisentan 10 mg tablets for oral administration Lot No. 17102393, expiration date January 2007, Lot No. 280200A0, expiration date January 2007), manufactured by drug substance Batch L0003139 (Lot No. L0001848) having a of
The respective batch size of the (R0135002), 5 mg (R0136002), 10 mg (R0137002) and 10 mg tablets (20137001) test tablets was not indicated, . The respective batch size of the (L0001849), 5 mg (L0001851) and 10 mg (L0001848) reference tablets was not indicated, . The batch size of the 5 mg and 10 mg formulations tested fulfilled the minimum size requirements.

Design

This was an open-label, randomized, 2 period (for 5 mg tablets) or 3-period (for 10 mg tablets) crossover, single center study. A total of 65 healthy subjects, males and females (with no child bearing potential) in the age between 18 and 55 y, were to be enrolled to ensure that 60 subjects (20 subjects for each dose group) complete both treatment periods with the and 5 mg tablets and the 3 treatment periods with the 10 mg tablets. Subjects were admitted to the Unit the night prior to dosing of each treatment period and remained confined in the Unit until Day 3 of each treatment period. Between administrations of a single dose of study drug in each treatment period, there was a 6 day wash-out period. All subjects were to take the tablets after an overnight fast together with 240 mL water. Concomitant medications, with the exception of 3 doses of acetaminophen at 1 g each or less were prohibited for the duration of the study. In addition, no foods or substances known to interfere with cytochrome P450 isozymes could be consumed, including tobacco, alcohol, and grapefruit containing products.

A study schematic (treatments with test formulations are denoted with A (5mg) and A or B (10 mg) and treatments with the test formulations are denoted with R) and a schedule of activities is shown in Figure 9.1 and Table 9.1, respectively.
**Table 9.1 Schedule of Assessments**

<table>
<thead>
<tr>
<th>Study Day</th>
<th>Screening Visit</th>
<th>In-House Phase of Study or Treatment Period</th>
<th>Clinic Discharge</th>
<th>Follow-Up 3 to 7 Days after Last Dose of Study Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>210</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>211</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
</tbody>
</table>

**PK Profiling**

Blood samples for the determination of ambrisentan plasma concentrations were collected at the following times after dosing on Day 1: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 18, 24 and 48 h.

**PK Analysis**
Non-compartmental methods using the software WinNonlin™ (Version 4.0.1, Pharsight Corp,) were utilized were used to compute the following parameters:

Cmax, tmax, tlag, AUC0-tlast, AUC0-∞, λz and t1/2

The sponsor did not provide information as to the criteria used to determine the slope of the terminal log linear phase and the method used for computing AUC0-tlast.

All plasma samples concentration values reported as “No Results (NR)” were treated as missing and are labeled in the data set as “-”. The below the quantifiable limit (BLQ) values that occurred prior to the first measurable concentration were treated as zero. All other BLQ values were treated as missing and set to “-”.

Bioassay

The plasma concentrations of ambrisentan were measured by a validated, specific LC-MS/MS assay by

Statistical Analysis

Separate analyses of variance models were fit to log-transformed AUC0-tlast, AUC0-∞, and Cmax for each dose group. Models included effects of treatment sequence, random subject within sequence, treatment, and period. Estimates of geometric mean ratios for the comparison between test and reference formulations at each dose level were computed with 90% confidence intervals (CI). The hypothesis of non-bioequivalence of test and reference formulations was rejected if the 90% CI for AUC0-tlast, AUC0-∞ and Cmax geometric mean ratios were within 80-125%. Comparisons of tmax with test and reference formulations at each dose level were performed using the Wilcoxon signed rank test.

An exploratory analysis with Cmax, AUC0-tlast and AUC0-∞ examined dose proportionality across dose groups. The analyses were performed separately with the test formulations using the power model ln (parameter) =a + b • ln dose), where a is the intercept and b is the slope. The slope estimate and 95% CI (2-sided) were computed. If the slope is approximately 1.0 dose proportionality can be concluded.

An estimate of intra-subject CV, assumed common to all formulations within each dose group, was estimated from the model residual error. The Pitman-Morgan adjusted F test was evaluated for evidence of unequal variability between test and reference formulations.

Results

Sixty-five subjects, 55 males and 10 females, of mean age 34.5 y and mean weight 79.9 kg, were enrolled, and 57 subjects completed the study.
In Group 1, 1 subject (01-106) withdrew consent during Period 2 due to refusal to use an IV catheter and another subject (01-121) was lost to follow-up.

In Group 2 (5 mg) 5 subjects were withdrawn due to noncompliance: Subject 01-205 after Period 2 for refusal to participate in end of study procedures, Subjects 01-212 and 01-213 for not returning for the Period 2 check-in, Subject 01-216 for not returning for the end of study procedures and Subject 01-217 for a positive drug screen at the Period 2 check-in.

In Group 3 (10 mg) 1 subject (01-322) was discontinued during Period 2 due to a streptococcal pharyngitis.

**Data Sets Analyzed for PK**

In Group 1, 20 subjects were included in the analysis. Subject 01-106 was not considered evaluable for PK analysis as he did not have sufficient plasma data after Treatment A1.

In Group 2 (5 mg) 19 subjects were included in the analysis. Subjects 01-212, 01-213, and 01-217 were considered not evaluable because they only received 1 dose during period 1.

In Group 3 (10 mg) 20 subjects were included in the analysis. Subject 01-322 was considered not evaluable for PK analysis because he only received 1 dose during Period 1.

The analysis of variance analysis did not show evidence for sequence or period difference.

Mean plasma concentrations and derived measures of bioavailability/bioequivalence are shown for test and reference formulations of ambrisentan at the __________ dose level in Figures 11.1 and Table 11.2, respectively.
Figure 11.1 Plasma Concentration-Time Profiles of Ambrisentan Following a Single Oral Dose of Ambrisentan from Test Product A1 (Test Drug A) or Reference Product R1 (Reference Drug) (Linear Scale)

Error bars represent SDs from the arithmetic mean
Source: Summary Figure 14.4.1

Table 11.2 Comparison of Ambrisentan Pharmacokinetic Parameters Following Treatment A1 (Test Drug A) and Treatment R1 (Reference Drug)

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>Treatment</th>
<th>Arithmetic Mean (SD)</th>
<th>Geometric Mean</th>
<th>Geometric Mean Ratio and 90% CI (A1/R1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ (ng/mL)</td>
<td>A1</td>
<td>203.5 (56.8) n=20</td>
<td>199.1</td>
<td>94.1 (83.4, 106.2)</td>
</tr>
<tr>
<td></td>
<td>R1</td>
<td>217.1 (49.7) n=20</td>
<td>211.5</td>
<td></td>
</tr>
<tr>
<td>$\text{AUC}_{0-\infty}$ (ng*h/mL)</td>
<td>A1</td>
<td>1833.3 (353.0) n=20</td>
<td>1800.3</td>
<td>104.5 (97.3, 112.3)</td>
</tr>
<tr>
<td></td>
<td>R1</td>
<td>1762.5 (404.0) n=20</td>
<td>1722.7</td>
<td></td>
</tr>
<tr>
<td>$\text{AUC}_{0-\infty}$ (ng*h/mL)$^3$</td>
<td>A1</td>
<td>2110.0 (362.0) n=17</td>
<td>2096.3</td>
<td>105.9 (98.8, 113.5)</td>
</tr>
<tr>
<td></td>
<td>R1</td>
<td>2008.9 (576.3) n=16</td>
<td>1980.0</td>
<td></td>
</tr>
<tr>
<td>$t_{\text{max}}$ (hr)</td>
<td>A1</td>
<td>2.0 (1.0, 6.0) n=20</td>
<td>NA</td>
<td>p=0.27</td>
</tr>
<tr>
<td></td>
<td>R1</td>
<td>1.5 (1.0, 6.0) n=20</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>$t_{1/2}$ (hr)$^1$</td>
<td>A1</td>
<td>16.2 (5.0) n=17</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>R1</td>
<td>15.0 (3.7) n=18</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

Sources: Summary Table 14.2.4 and Summary Table 14.2.7

1 $t_{\text{max}}$ and $\text{AUC}_{0-\infty}$ could not be determined for three subjects in Treatment A1 and two subjects in Treatment R1

2 Geometric means were based on mixed model ANOVA and only included subjects that had $\text{AUC}_{0-\infty}$ values in Treatments A1 and R1

3 For $t_{0-\infty}$, median (minimum, maximum) values are reported and p-value of Wilcoxon signed rank test of hypothesis that median pair-wise T is R difference = 0

n = number of subjects included in the calculation of mean values
NA = not applicable/not calculated
Mean plasma concentrations and derived measures of bioavailability/bioequivalence are shown for test and reference formulations of ambrisentan at the 5 dose level in Figures 11.2 and Table 11.3, respectively.

Best Possible Copy

Appears This Way
On Original
Figure 11.3 Plasma Concentration-Time Profiles of Ambrisentan Following a Single Oral Dose of 10 mg Ambrisentan from Test Product A3 (10 mg Test Drug A) versus Reference Product R3 (10 mg Reference Drug) (Linear Scale)

Error bars represent SDs from the arithmetic mean
Source: Summary Figure 14.4.5
Figure 11.4 Plasma Concentration-Time Profiles of Ambrisentan Following a Single Oral Dose of 10 mg Ambrisentan from Test Product B3 (10 mg Test Drug B) versus Reference Product R3 (10 mg Reference Drug) (Linear Scale)

Error bars represent SDs from the arithmetic mean
Source: Summary Figure 14.4.5

Best Possible Copy

Appears This Way
On Original
### Table 11.4 Comparison of Ambrisentan Pharmacokinetic Parameters Following Treatment A3 (10 mg Test Drug A) and B3 (10 mg Test Drug B) and Treatment R3 (10 mg Reference Drug)

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>Treatment</th>
<th>Arithmetic Mean (SD)</th>
<th>Geometric Mean</th>
<th>Geometric Mean Ratio and 90% CI (A3/R3 or B3/R3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>A3</td>
<td>721.2 (190.5)</td>
<td>697.1</td>
<td>87.2 (79.3, 95.9)</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td>n = 21</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B3</td>
<td>803.0 (226.3)</td>
<td>783.6</td>
<td>98.0 (89.1, 107.8)</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td>n = 21</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R3</td>
<td>838.8 (222.2)</td>
<td>799.7</td>
<td>99.7 (95.5, 103.9)</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td>n = 21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-24&lt;/sub&gt; (ng·hr/mL)</td>
<td>A3</td>
<td>7573.7 (1674.7)</td>
<td>7381.7</td>
<td>96.3 (92.2, 100.4)</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td>n = 21</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B3</td>
<td>7277.9 (1542.1)</td>
<td>7131.4</td>
<td>99.9 (95.4, 104.5)</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td>n = 21</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R3</td>
<td>7643.0 (1651.8)</td>
<td>7407.5</td>
<td>97.2 (91.7, 101.0)</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td>n = 21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-∞&lt;/sub&gt; (ng·hr/mL)</td>
<td>A3</td>
<td>8419.9 (1911.2)</td>
<td>8195.3</td>
<td>99.7 (95.5, 103.9)</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td>n = 18</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B3</td>
<td>7998.2 (1583.2)</td>
<td>7896.3</td>
<td>96.2 (91.7, 101.0)</td>
</tr>
<tr>
<td></td>
<td>n = 18</td>
<td>n = 18</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R3</td>
<td>8621.4 (1870.7)</td>
<td>8207.6</td>
<td>99.9 (95.4, 104.5)</td>
</tr>
<tr>
<td></td>
<td>n = 20</td>
<td>n = 18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>t&lt;sub&gt;max&lt;/sub&gt; (hr)</td>
<td>A3</td>
<td>2.0 (1.0, 8.0)</td>
<td>NA</td>
<td>p = 0.39</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B3</td>
<td>1.5 (1.0, 4.0)</td>
<td>NA</td>
<td>p = 0.32</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R3</td>
<td>1.5 (1.0, 8.0)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (hr)</td>
<td>A3</td>
<td>18.1 (4.3)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>n = 21</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B3</td>
<td>18.4 (3.8)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>n = 18</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>R3</td>
<td>18.1 (4.3)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>n = 20</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sources: Summary Table 14.2.6 and Summary Table 14.2.9

1<sup>1</sup> t<sub>1/2</sub> and AUC<sub>0-∞</sub> could not be determined for three subjects in Treatment B3 and one subject in Treatment R3.

2<sup>2</sup> For t<sub>max</sub>, median (minimum, maximum) values are reported and p-value of Wilcoxon signed rank test of hypothesis that median pair-wise T - R difference = 0.

n = number of subjects included in the calculation of mean values

NA = not applicable/not calculated

Mean plasma concentrations and derived measures of bioavailability/bioequivalence are shown for test and reference formulations of ambrisentan at the 10 mg dose level in Figures 11.3 and 11.4 and Tables 11.4, respectively:

In all subjects and treatments ambrisentan was measurable in the first plasma sample (0.5 h) collected after administration. At the 10 mg level the plasma concentrations of ambrisentan could be followed up to 48 after administration in all 40 treatments. At the 5 mg dose level the plasma concentrations could be measured up to 48 h after administration in 37 of 38 treatments. At the
level the plasma concentrations of ambrisantan were measurable for 48 h in 17 of the 40 treatments. The ratio of mean AUC0-tlast/mean AUC0-∞ ranged between 0.87 to 0.91 indicating that the extrapolated part of AUC0-∞ is small.

The results indicate that the 90% CI for Cmax, AUC0-tlast and AUC0-∞ for the test formulations of ____ and 5 mg strength were bounded within the 80%-125% limits for bioequivalence. At the 10 mg dose level only the test formulation with a ____ fulfilled the criteria for bioequivalence with the reference formulation. In contrast, Cmax of the commercial 10 mg tablet with the ____ failed to meet the lower bioequivalence boundary. There was no statistically significant difference between the tmax values of the test and reference formulation at the 3 dose levels. Mean tmax among the commercial formulations ranged between 1.5 h and 3.0 h and among the clinical formulations between 1.5 h and 2.5 h. The half life of the apparent terminal log linear phase of ambrisantan ranged between 15 h and 18 h.

The respective slopes for Cmax and AUC for the A1, A2 and A3 test formulation treatments were 0.91 (95% CI: 0.78, 1.04) and 1.02 CI: 95% CI: 0.89, 1.15) indicating that the PK after single dose administration is dose proportionate.

The intra-subject variation of Cmax and AUC ranged between 11.4% and 21.8% and 8.1% and 10.7%, respectively.

Conclusions

The ____ and 5 mg ____ commercial formulations are bioequivalent to the respective clinical service formulations. The commercial 10 mg formulation ____ does not meet the bioequivalence criteria for Cmax. In contrast, the commercial 10 mg formulation ____ meets the bioequivalence criteria.

The PK of ambrisantan after administration of the commercial formulations were dose proportional. The intra-subject variation for Cmax and AUC ranged between 11.4% and 21.8% and 8.1% and 21.8%, respectively.

Comments

1. The criteria applied in determining the slope of the log linear terminal phase are not stated in the report. Also, the method used to compute AUC0-tlast is not stated in the report.

2. Possible causes for the failure of the 10 mg commercial formulation of ____ to meet the bioequivalence criteria were not discussed in the report.

Study Report: AMB-106”APhase 1, Open-Label Study To Evaluate the Potential for a Pharmacodynamic and/or Pharmacokinetic Interaction of Ambrisantan with a Single Dose of Racemic Warfarin in Healthy Adult Volunteers”
Study Investigator and Site:

Objectives

Primary

To assess the effects of multiple doses of ambrisentan on the pharmacodynamics (PD) of a single dose of racemic warfarin, as determined by assessments of prothrombin time (PT) and International Normalized Ratio (INR)

Secondary

To assess the effect of multiple doses of ambrisentan on the pharmacokinetics (PK) of a single dose of warfarin (S- and R-enantiomers)
To assess the effect of a concomitant, single dose of warfarin on the PK of multiple doses of ambrisentan
To examine the safety and tolerability of ambrisentan in the presence of a single dose of warfarin

Formulations

Ambrisentan was provided by Myogen, Inc., as 10 mg film-coated immediate release tablets. The pink tablets were manufactured by . Commercially available warfarin was provided to the clinical site as 5 mg tablets for oral administration, manufactured by Lot No. ETD286A. The packager Lot No. for the ambrisentan tablets was L0001848 ( article/material No.17102293, Lot No. 280100A0).

Design

This was an open-label, non-randomized, 2-period crossover, single center study as shown in the below study schematic:
Twenty-two (22) subjects were to be enrolled to ensure that 18 subjects completed the study. On Day 1, subjects were administered a single 25 mg dose of warfarin. Prothrombin Time (PT) and International Normalization Ratio (INR) and the PK of the S- and R-enantiomers of warfarin were assessed at scheduled intervals for 96 h after the Day 1 warfarin dose. Subjects then received a once daily 10 mg of ambrisentan on Days 5 through 16. Blood samples were collected on Days 10 through 12 to assess attainment of steady-state. On Day 12, blood samples were taken over a 24 h period for PK assessment of ambrisentan. PT and INR and the PK profile of the warfarin enantiomers were assessed at scheduled intervals for 96 h after the Day 13 warfarin dose and the ambrisentan doses of Days 13 through 17.

Subjects were admitted to the unit the night before dosing and remained in the clinic until Day 17 or when their INR value was < 1.2, whichever was longer.

The scheduled activities of the study are shown in Table 9.1:
Pharmacokinetic Profiling

Blood samples for the determination of the S- and R-enantiomers of warfarin were collected at the following times on Days 1 and 13: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 72, and 96 h post-dose.

Blood samples for the determination of ambrisentan plasma concentrations were collected at the following times on Days 12 and 13: Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24 h post-dose. In addition blood samples were collected for determining trough levels on Days 10 through 13.

Bioassay

Plasma concentrations of ambrisentan were determined by a validated LC/MS/MS method with an LOQ of \( y/\text{mL} \).

Plasma concentrations of S- and R-warfarin were determined by a validated LC/MS/MS method with a LLOQ of \( z/\text{g/mL} \).

PK analysis

Appears This Way
On Original
The plasma concentration-time data of warfarin (S- and R- enantiomers) and ambrisentan were
determined using non-compartmental methods. The software WinNonlin™ was used (inNonlin

For the S- and R-enantiomers of warfarin the following parameters were determined: Cmax,
tmax, tlag, AUC0-tlast, AUC0-00, λz, t1/2, CL/F and Vz/F.

For ambrisentan the following parameters were determined: Cmax, ss, Cmin, ss, Cavg, ss, tmax, ss,
AUC0-τ, ss, AUC0-tlast, ss, AUC0-00, ss, λz, t1/2, CLss/F (Dose/AUC0-τ, ss) and Vz, ss/F
(Dose/(λz • AUC0-τ, ss))

**PK Data Analysis**

To assess the effect of multiple doses of ambrisentan on the PK of warfarin (S- and R-
enantiomers), individual within-subject pair-wise differences were summarized for the natural
logarithm of the S- and R-enantiomers Cmax, AUC0-tlast and AUC0-00. Geometric mean ratios
of Day 13 to Day 1 were reported with 90% CI. The ratios and CIs were expressed as a
percentage and compared to the standard criterion for bioequivalence (90% CI within 80-125%).
The Wilcoxon signed rank test was used to determine the differences in tmax on Days 13 and 1.

To assess the possible impact of the presence of warfarin on the PK of ambrisentan the same
statistical methods were used. The differences in the parameters Cmax, ss, Cmin, ss and AUC0-
τ, ss and tmax between Days 13 and 12 were computed.

To assess attainment of steady-state of ambrisentan on Days 10 through 13 the natural log
transformed trough concentrations were subjected to an analysis of variance model that included
a random subject effect and fixed day effect. The following contrasts were compared: Day 10 vs
average of Days 10-13, Day 11 vs average of Days 12-13, and Day 12 vs Day 13. The lower
bound of each 90% CI about these contrasts was compared to an 80% equivalence criterion. If
for example the lower bound of the Day 10 vs Day 11 through 13 contrast was above 80%, then
this supported an inference that ambrisentan steady-state was achieved by Day 10.

**PD Profiling**

Blood samples for the determination of PT and INR were collected after a single dose of
warfarin in the presence and absence of ambrisentan at the same times as for the determination of
the PK parameters on Days 1-5 and 13-17. Lmax (maximum observed value of PT or INR) and
the associated time, tmax, and AUE0-tlast (area under the PT or INR time curve from time zero
the last measurable concentration) using the linear trapezoidal rule were determined. Description
and validation performance for PT and INR assays were not included in the study report.

**PD Data Analysis**

To assess the effect of multiple doses of ambrisentan on the PD of warfarin, individual within-
subject pair-wise differences were summarized for the natural logarithm transformed Lmax and
AUE0-tlast on Days 1 and 13 for PT and INR. Treatment contrasts (Day 13 vs Day1), 2-sided